Umbelliferone and eriodictyol suppress the cellular entry of SARS-CoV-2.

Publication date: Jun 28, 2023

Artemisia argyi (A. argyi), also called Chinese mugwort, has been widely used to control pandemic diseases for thousands of years since ancient China due to its anti-microbial infection, anti-allergy, and anti-inflammation activities. Therefore, the potential of A. argyi and its constituents in reducing the infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was investigated in this study. Among the phytochemicals in A. argyi, eriodictyol and umbelliferone were identified to target transmembrane serine protease 2 (TMPRSS2) and angiotensin-converting enzyme 2 (ACE2) proteins, the essential factors for the cellular entry of SARS-CoV-2, in both FRET-based enzymatic assays and molecular docking analyses. These two ingredients of A. argyi suppressed the infection of ACE2-expressed HEK-293 T cells with lentiviral-based pseudo-particles (Vpp) expressing wild-type and variants of SARS-CoV-2 spike (S) protein (SARS-CoV-2 S-Vpp) via interrupting the interaction between S protein and cellular receptor ACE2 and reducing the expressions of ACE2 and TMPRSS2. Oral administration with umbelliferone efficiently prevented the SARS-CoV-2 S-Vpp-induced inflammation in the lung tissues of BALB/c mice. Eriodictyol and umbelliferone, the phytochemicals of Artemisia argyi, potentially suppress the cellular entry of SARS-CoV-2 by preventing the protein binding activity of the S protein to ACE2.

Open Access PDF

Concepts Keywords
Biosci ACE2
China Artemisia argyi
Coronavirus Eriodictyol
Mice SARS-CoV-2 variants
Pandemic TMPRSS2


Type Source Name
disease MESH infection
disease MESH allergy
disease MESH inflammation
disease VO Severe acute respiratory syndrome coronavirus 2
drug DRUGBANK Serine
drug DRUGBANK Angiotensin II
disease MESH syndrome
disease VO USA
disease MESH COVID 19
disease VO organization
disease MESH reinfection
disease IDO host
disease IDO replication
pathway KEGG Endocytosis
disease VO Viruses
disease VO effectiveness
disease MESH oxidative stress
disease MESH tumor
disease MESH middle east respiratory syndrome
pathway KEGG Viral replication
drug DRUGBANK Linoleic acid
disease MESH clinical relevance
disease MESH nonalcoholic fatty liver
disease VO dose
disease IDO assay
disease VO NAP
disease VO viability
disease MESH granuloma
disease MESH fibrosis
drug DRUGBANK Papain
drug DRUGBANK L-Cysteine
drug DRUGBANK Coenzyme M
drug DRUGBANK Stavudine
disease MESH emergency
drug DRUGBANK Hispidulin
drug DRUGBANK Echinacea
drug DRUGBANK Montelukast
disease VO Glycoprotein
disease VO frequency
drug DRUGBANK Amino acids
drug DRUGBANK L-Aspartic Acid
drug DRUGBANK L-Arginine
drug DRUGBANK Glutamic Acid
drug DRUGBANK L-Tyrosine
drug DRUGBANK Glycine
drug DRUGBANK L-Lysine
drug DRUGBANK Dextrose unspecified form
drug DRUGBANK Medical air
drug DRUGBANK Dimethyl sulfoxide
disease MESH vesicular stomatitis
disease VO Lentivirus
drug DRUGBANK Tromethamine
disease VO time
disease VO protocol
disease VO BPS
disease MESH pulmonary inflammation
disease IDO process
drug DRUGBANK Water
drug DRUGBANK Sodium lauryl sulfate
drug DRUGBANK Indoleacetic acid
drug DRUGBANK Ethanol
drug DRUGBANK Chymotrypsin

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *